55.25
+5.01(+9.97%)
Currency In USD
| Previous Close | 50.24 |
| Open | 49.78 |
| Day High | 56.39 |
| Day Low | 46.85 |
| 52-Week High | 56.39 |
| 52-Week Low | 12.25 |
| Volume | 1.27M |
| Average Volume | 519,063 |
| Market Cap | 1.53B |
| PE | -19.59 |
| EPS | -2.82 |
| Moving Average 50 Days | 46.81 |
| Moving Average 200 Days | 31.11 |
| Change | 5.01 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $3,250 as of February 11, 2026 at a share price of $55.25. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,673.74 as of February 11, 2026 at a share price of $55.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 9:15 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc.
Jan 08, 2026 11:00 PM GMT
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovativ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o